PDCD1 and neoplasm: The combination of dabrafenib (BRAFi), trametinib (MEKi), and murine anti-PD-1 antibody led to an improved tumor response, visible as a decrease in tumor volume as well as an increase in the number of effector and helper T lymphocytes within the tumor niche, compared to monotherapy in mouse melanoma models [45,46].